1. Abstract
The Changes in Sexual Functioning Questionnaire (CSFQ) is a standardized psychometric instrument designed to evaluate sexual functioning, characterize sexual dysfunction, and monitor longitudinal variations in sexual response across both clinical and research settings. Developed by Anita H. Clayton and Elizabeth L. McGarvey at the University of Virginia School of Medicine, the CSFQ addresses a historically critical diagnostic gap by providing gender-tailored versions—the Female Clinical Version (CSFQ-F-C) and the Male Clinical Version (CSFQ-M-C)—as well as their validated 14-item short forms (CSFQ-14-F and CSFQ-14-M). The measurement tool operates on a multi-dimensional architecture corresponding to the physiological phases of the human sexual response cycle. It systematically measures five distinct clinical domains: Sexual Pleasure/Satisfaction, Sexual Desire/Frequency, Sexual Desire/Interest, Sexual Arousal/Excitement, and Sexual Orgasm/Completion.
Composed of 14 core scored items in its abbreviated form, the instrument employs a 5-point Likert scale tailored to specific behavioral frequencies or qualitative appraisals of enjoyment, with reverse-scored items to account for adverse responses such as arousal loss or painful orgasm. Psychometric evaluations across diverse populations—including psychiatric cohorts receiving psychotropic medications, oncology survivors, postmenopausal women, and non-clinical reference groups—demonstrate high internal consistency, with Cronbach’s alpha coefficients typically ranging from .89 to .90 for total scores. Criterion and construct validities are corroborated by robust convergence with legacy metrics such as the Derogatis Interview for Sexual Functioning (DISF) and established clinical diagnostic benchmarks. The instrument’s diagnostic cutoffs (total scores ≤ 41 for females and ≤ 47 for males) reliably identify clinically significant sexual morbidity, making the CSFQ a gold-standard assessment in psychopharmacology, clinical psychiatry, sex therapy, and behavioral medicine.
2. Keywords
Changes in Sexual Functioning Questionnaire, CSFQ, CSFQ-14, psychopharmacology, sexual dysfunction, female sexual interest/arousal disorder, erectile dysfunction, antidepressant-induced sexual dysfunction, sexual response cycle, psychometrics, libido assessment, clinical psychiatry, Anita Clayton
3. Authors
The Changes in Sexual Functioning Questionnaire was conceptualized, constructed, and empirically validated by:
- Anita H. Clayton, M.D. — David C. Wilson Professor of Psychiatry and Neurobehavioral Sciences, Professor of Clinical Obstetrics and Gynecology, Department of Psychiatry and Neurobehavioral Sciences, University of Virginia School of Medicine, Charlottesville, Virginia, USA. Address: 2955 Ivy Road, Suite 210, Charlottesville, VA 22903; Email: [email protected].
- Elizabeth L. McGarvey, Ed.D. — Professor of Public Health Sciences and Psychiatric Medicine, Department of Public Health Sciences, University of Virginia School of Medicine, Charlottesville, Virginia, USA.
- Collaborating Investigators: Georgia J. Clavet, B.S., Lawrence A. Piazza, M.D., and Alan Keller, Ph.D., who co-authored early psychometric construction, cross-sectional validation trials, and factor-analytic structural models.
4. Purpose
The primary purpose of the Changes in Sexual Functioning Questionnaire (CSFQ) is to provide clinicians, clinical psychopharmacologists, and behavioral researchers with an empirically rigorous, sensitive, and standardized measurement system capable of delineating baseline sexual health, identifying specific phases of sexual impairment, and tracking treatment-emergent changes over time. Historically, clinical inquiry into sexual pathology was impeded by two distinct structural biases: first, an overwhelming diagnostic preoccupation with male genital tumescence (such as erectile dysfunction), which relegated complex female sexual subjective experiences—such as desire, receptive lubrication, and emotional satisfaction—to the diagnostic periphery; and second, the confounding overlap between endogenous psychiatric disorders (e.g., major depressive disorder) and psychotropic medication-induced sexual adverse events.
From a theoretical and clinical perspective, the CSFQ was specifically engineered to overcome these empirical limitations. Antidepressant agents—particularly selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs)—induce broad-spectrum sexual adverse effects in 30% to 70% of treated patients. Because psychiatric illness itself frequently impairs libido, clinicians require a precision metric that distinguishes between pre-existing lifelong dysfunction, episode-associated sexual decline, and pharmacological iatrogenesis. The initial 35-to-36-item interview format (CSFQ-I) established this comprehensive baseline across 30 to 45 minutes of clinical interaction. However, the subsequent distillation into the 14-item self-report questionnaire (CSFQ-14-F for females and CSFQ-14-M for males) preserved psychometric rigor while dramatically accelerating administration time to under five minutes, making routine serial monitoring feasible in outpatient practices, clinical drug trials, and epidemiological surveys.
Beyond psychiatric medicine, the CSFQ serves as a critical evaluative instrument across a wide variety of medical disciplines. It is widely employed in psycho-oncology (notably among survivors of gynecological and breast malignancies), endocrinology (evaluating menopause, hypogonadism, and metabolic syndrome), urology and urogynecology (benign prostatic hyperplasia, chronic pelvic pain, and vulvodynia), and neurology (spinal cord injury, multiple sclerosis). By grounding assessment within the discrete physiological and psychological components of the sexual response cycle, the CSFQ enables clinicians to strategically tailor interventions—whether that involves switching a neurochemical agent, prescribing phosphodiesterase-5 inhibitors, adjusting hormone therapies, or engaging in targeted psychosexual couples therapy.
5. Psychological Construct
The Changes in Sexual Functioning Questionnaire operationalizes human sexual functioning not as a monolithic state, but as a sequential, multi-phasic construct comprising distinct yet interrelated physiological, behavioral, and subjective dimensions. The 14-item inventory maps systematically onto five clinical domains alongside overall sexual adjustment:
Sexual Pleasure / Global Satisfaction
Measured primarily by Item 1, this subscale captures the individual’s subjective cognitive and emotional evaluation of their current sex life relative to their personal historical peak (“Compared with the most enjoyable it has ever been, how enjoyable or pleasurable is your sexual life right now?”). This dimension recognizes that sexual health transcends the mechanical execution of coitus; it encompasses affective resonance, relational intimacy, and hedonic fulfillment. A decrement in pleasure often serves as an early indicator of sexual demoralization or anhedonia secondary to affective disorders.
Sexual Desire / Frequency
Represented by Items 2 and 3, this behavioral construct quantifies the objective behavioral cadence of sexual engagement (intercourse, oral sex, partnered manual stimulation, or masturbation) alongside the subjective frequency of spontaneous appetite or biological drive to participate in sexual acts. It delineates between physical opportunity and the conscious, internally generated motivation to initiate or engage in intimacy.
Sexual Desire / Interest
Encompassed by Items 4, 5, and 6, this cognitive-affective subscale assesses sexual fantasy, erotic mentation, appetitive cognition, and responsiveness to environmental erotic stimuli (e.g., erotic media, literature, or artwork), as well as the hedonic pleasure derived from daydreaming or thinking about sex. This dimension captures the appetitive phase of sexual behavior, providing insight into hypoactive sexual desire conditions that operate independently of actual physical encounters.
Sexual Arousal / Excitement
Spanning Items 7, 8, and 9 (with Item 10 tracking arousal maintenance), this physiological and psychological construct gauges the ease, rapidity, and frequency of peripheral vasocongestive and central neurobiological arousal. In the female version (CSFQ-F-C), it specifically targets subjective arousal alongside physiological manifestations of excitement, notably adequate vaginal lubrication. In the male parallel (CSFQ-M-C), it evaluates the facility, consistency, and maintenance of penile erection. Item 10, which assesses premature arousal loss, provides critical differential data on autonomic instability during intimate encounters.
Sexual Orgasm / Completion
Captured by Items 11, 12, and 13 (with Item 14 monitoring dyspareunia or coital algia), this domain evaluates the orgasmic release phase. It measures the frequency of orgasm attainment, the individual’s sense of volitional control over reaching climax (“Are you able to have an orgasm when you want to?”), and the qualitative intensity or pleasure experienced during climax. Item 14 assesses adverse outcomes such as painful orgasm (anodynia or dysorgasmia), capturing somatic pain pathways that inhibit sexual completion.
6. Theoretical Framework
The conceptual architecture of the CSFQ is anchored in the foundational physiological and psychobiological models of the human sexual response cycle formulated by William Masters and Virginia Johnson (1966) and subsequently reformulated by Helen Singer Kaplan (1974, 1979). Masters and Johnson established the classic four-stage human sexual response sequence: Excitement, Plateau, Orgasm, and Resolution. While groundbreaking, this somatic model concentrated almost exclusively on peripheral genital physiology (vasocongestion, myotonia, tumescence, and muscular contractions), largely omitting central appetitive motivation and subjective psychological readiness.
Recognizing this omission, Helen Singer Kaplan integrated psychodynamic and behavioral formulations into a triphasic neurophysiological model comprising Desire, Arousal, and Orgasm. Kaplan demonstrated that distinct neurochemical and physiological subsystems regulate these three phases: central dopaminergic and neuroendocrine circuits drive desire; peripheral parasympathetic and autonomic pathways regulate vasocongestive arousal; and sympathetic spinal efferents control rhythmic orgasmic contractions. Clayton and colleagues operationalized Kaplan’s triphasic paradigm within the CSFQ by segmenting desire into dual facets—spontaneous biological frequency and cognitive-imaginative interest—while preserving explicit, objective evaluations of arousal and orgasmic completion.
Furthermore, the CSFQ reflects modern biopsychosocial frameworks of sexual medicine and aligns with diagnostic evolutions outlined in the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV through DSM-5-TR). It acknowledges that human sexual expression is modulated by continuous bidirectional interactions between biological substrates (e.g., neurochemical receptors, vascular tone, gonadal steroids), psychological processes (e.g., mood, anxiety, body image, self-efficacy), and contextual factors (e.g., relationship harmony, environmental stress). In doing so, the scale avoids treating sexual functioning merely as an isolated physical reflex, instead measuring subjective hedonic evaluation as an overarching dimension of psychological wellbeing.
7. Validity
The psychometric validity of the Changes in Sexual Functioning Questionnaire has been extensively corroborated across diverse clinical, non-clinical, and multi-linguistic cohorts.
Construct and Criterion-Related Validity
During the initial validation of the clinical interview format (CSFQ-I) and its subsequent 14-item self-report derivations, Clayton, McGarvey, Clavet, and Piazza (1997) evaluated construct validity by comparing non-depressed community volunteers against actively depressed psychiatric outpatients. The depressed cohort exhibited statistically significant decrements across all CSFQ subscale scores and total scores ($p < .001$), confirming the instrument’s capacity to discriminate between functionally unimpaired individuals and those experiencing clinical affective disorders. Receiver operating characteristic (ROC) curves derived from clinical trials established critical diagnostic thresholds: a cutoff score of ≤ 41 for females (CSFQ-F-C) and ≤ 47 for males (CSFQ-M-C), maximizing diagnostic sensitivity and specificity for identifying sexual dysfunction.
Convergent and Concurrent Validity
Concurrent validity was demonstrated through correlation analysis with legacy gold-standard sexual inventories, predominantly the Derogatis Interview for Sexual Functioning (DISF/DISF-SR) developed by Leonard R. Derogatis. The CSFQ total and subscale scores exhibited high, statistically significant positive correlations with corresponding DISF domains ($r = .65$ to $.82$, $p < .001$). Furthermore, concurrent trials tracking sexual side effects of novel antidepressants (Clayton et al., 2002) confirmed that the CSFQ is highly sensitive to pharmacologically mediated alterations in serotonin and dopamine transmission, detecting subtle emergent deficits in lubrication, erection, and ejaculatory latency.
Discriminant and Predictive Validity
The CSFQ consistently demonstrates robust discriminant validity, differentiating between generalized global hypoactivity and isolated phase dysfunctions (such as anorgasmia with intact desire, or erectile dysfunction with preserved appetitive fantasy). In psycho-oncological studies involving gynecological cancer survivors (Lagana, McGarvey, Classen, & Koopman, 2001) and endocrinological evaluations of surgical menopause (Warnock et al., 2005), the CSFQ reliably identified focal physiological impairments (e.g., neurogenic vaginal dryness) without confounding them with general psychological demoralization. Longitudinal sensitivity to therapeutic change has been repeatedly documented in clinical pharmacological trials, in which patients switching from high-risk SSRIs to agents with dopaminergic/noradrenergic profiles (e.g., bupropion) showed measurable, statistically significant increases in CSFQ total and arousal/orgasm subscale scores.
8. Reliability
The Changes in Sexual Functioning Questionnaire exhibits strong, cross-validated reliability across its various iterations and demographic translations.
Internal Consistency
In the landmark psychometric validation of the 14-item short-form inventory conducted by Keller, McGarvey, and Clayton (2006), the instrument demonstrated outstanding internal consistency. The overall scale achieved a Cronbach’s alpha coefficient of α = .90 for the female version (CSFQ-14-F) and α = .89 for the male version (CSFQ-14-M). Evaluation of individual subscales revealed moderate-to-high internal consistency values, typically ranging from .72 to .86 across the dimensions of desire frequency, desire interest, arousal, and orgasm completion. The pleasure item, serving as a single-item global metric, exhibited strong item-total correlation coefficients ($r = .55$ to $.70$).
Test-Retest Reliability and Temporal Stability
Test-retest reliability assessments conducted across stable clinical outpatients and healthy control subjects over two- to four-week intervals revealed substantial temporal stability. Intraclass correlation coefficients (ICCs) and Pearson product-moment correlations for the CSFQ total score consistently exceeded $r = .80$ ($p < .001$), with subscale temporal correlations ranging from .73 to .85 in populations without intervening pharmacologic or psychotherapeutic modifications. The reliability parameters of cross-cultural adaptations, including the Spanish translation validated by Bobes and colleagues (2000), mirrored the psychometric properties of the original English instrument, reporting Cronbach’s alpha coefficients exceeding .85 and stable test-retest coefficients across 51 linguistically harmonized translations worldwide.
9. Factor Analysis
The structural validity of the CSFQ has been examined through both Exploratory Factor Analysis (EFA) and Confirmatory Factor Analysis (CFA), substantiating its multi-dimensional conceptual architecture.
Exploratory Factor Structure
Initial exploratory factor analytic procedures using principal axis factoring with promax and varimax rotations (Clayton, McGarvey, Clavet, & Piazza, 1997; Keller et al., 2006) supported a robust five-factor solution accounting for the majority of the total variance (> 65%). The empirical loading patterns systematically reflected the theoretical phases of the human sexual response cycle:
- Factor 1: Desire / Interest — Heavily loaded by Items 4, 5, and 6 (factor loadings ranging from .68 to .85), capturing cognitive fantasy, appetitive media engagement, and internal sexual mentation.
- Factor 2: Orgasm / Completion — Defined by Items 11, 12, and 13 (loadings ranging from .72 to .88), clustering orgasmic frequency, orgasmic reliability/control, and hedonic climax intensity.
- Factor 3: Arousal / Excitement — Composed of Items 7, 8, and 9 (loadings ranging from .64 to .81), measuring biological and subjective arousal alongside genital physiological response (lubrication or erection).
- Factor 4: Desire / Frequency — Comprising Items 2 and 3 (loadings ranging from .70 to .86), representing behavioral participation and spontaneous appetitive frequency.
- Factor 5: Pleasure / Global Satisfaction — Anchored by Item 1, functioning as an overarching hedonic marker.
Items 10 (arousal maintenance/distractibility) and 14 (painful orgasm) exhibited complex secondary loadings across factors, reflecting their role as clinical adverse modifiers. Consequently, standard scoring protocols retain Items 10 and 14 within the Total CSFQ score while excluding them from the five discrete phase-specific subscales.
Confirmatory Factor Analysis and Model Fit
Confirmatory factor analyses testing the hypothesized five-factor oblique model have consistently indicated acceptable to excellent goodness-of-fit indices across gender groups. Fit criteria yielded a Comparative Fit Index (CFI) ≥ .94, a Non-Normed Fit Index (NNFI/TLI) ≥ .92, and a Root Mean Square Error of Approximation (RMSEA) ≤ .058 (90% CI [.048, .068]), confirming that the multi-dimensional partitioning of the sexual response cycle into desire, arousal, orgasm, and pleasure provides a structurally sound psychometric framework.
10. Instrument / Measurement Tool
The operational administration, scoring, and diagnostic parameters of the CSFQ are structured as follows:
- Instrument Type: Standardized Clinical Rating Scale and Patient-Reported Outcome Measure (PROM); available as a clinician-administered semi-structured interview (CSFQ-I) and self-administered short form (CSFQ-14).
- Target Populations: Adult females and males (aged 18+) across psychiatric, medical, and healthy non-clinical cohorts.
- Item Count: 14 primary scored items on the brief clinical versions (CSFQ-F-C for females and CSFQ-M-C for males). (The original interview edition contains 35 items for females and 36 items for males).
- Response Scale: 5-point Likert-type scale specific to each item, querying either frequency (1 = Never, 2 = Rarely, 3 = Sometimes, 4 = Often, 5 = Every Day / Always) or qualitative hedonic evaluation (1 = No Enjoyment or Pleasure to 5 = Great Enjoyment or Pleasure).
- Administration Time: Approximately 4 to 5 minutes for the CSFQ-14 self-report; 30 to 45 minutes for the extensive CSFQ-I clinical interview.
- Scoring Architecture: Total Score is calculated by summing all 14 items (theoretical range: 14 to 70). Higher scores reflect superior sexual functioning; lower scores indicate greater sexual impairment. Items 10 and 14 are reverse-scored prior to summation.
- Subscale Structural Breakdown:
- Pleasure / Overall Satisfaction: Item 1 (Score range: 1 to 5)
- Desire / Frequency: Item 2 + Item 3 (Score range: 2 to 10)
- Desire / Interest: Item 4 + Item 5 + Item 6 (Score range: 3 to 15)
- Arousal / Excitement: Item 7 + Item 8 + Item 9 (Score range: 3 to 15)
- Orgasm / Completion: Item 11 + Item 12 + Item 13 (Score range: 3 to 15)
- Diagnostic Modifiers (Total Score only): Item 10 (Arousal maintenance) + Item 14 (Painful orgasm)
- Established Diagnostic Cutoff Scores for Sexual Dysfunction:
- Female Clinical Scoring (CSFQ-F-C):
- Total Score: ≤ 41.0
- Pleasure Subscale: ≤ 4.0
- Desire / Frequency Subscale: ≤ 6.0
- Desire / Interest Subscale: ≤ 9.0
- Arousal / Excitement Subscale: ≤ 12.0
- Orgasm / Completion Subscale: ≤ 11.0
- Male Clinical Scoring (CSFQ-M-C):
- Total Score: ≤ 47.0
- Pleasure Subscale: ≤ 4.0
- Desire / Frequency Subscale: ≤ 8.0
- Desire / Interest Subscale: ≤ 11.0
- Arousal / Excitement Subscale: ≤ 13.0
- Orgasm / Completion Subscale: ≤ 13.0
- Female Clinical Scoring (CSFQ-F-C):
11. Permissions & Fee and Test Year
The Changes in Sexual Functioning Questionnaire was initially conceptualized and published in 1997 by Anita H. Clayton, Elizabeth L. McGarvey, and colleagues at the University of Virginia School of Medicine. Further refinement and validation of the 14-item short forms (CSFQ-14-F and CSFQ-14-M) were finalized and published by Keller, McGarvey, and Clayton in 2006.
Copyright and Licensing: All versions of the CSFQ (including CSFQ-I, CSFQ-14-F, CSFQ-14-M, and linguistic translations) are protected under copyright held by Dr. Anita H. Clayton. Academic clinicians and non-profit researchers may typically obtain authorization for clinical and academic investigation upon written request to the primary author. Use in industry-sponsored trials, commercial pharmaceutical protocols, or fee-for-service digital implementations requires formal licensing agreements and royalty clearance. Requests for clinical administration packets, scoring keys, or research permissions should be addressed to:
Anita H. Clayton, M.D.
David C. Wilson Professor, Department of Psychiatry and Neurobehavioral Sciences
University of Virginia Health System
2955 Ivy Road, Suite 210, Charlottesville, VA 22903
Telephone: +1 (434) 243-4646 | E-mail: [email protected]
12. References
Bobes, J., Gonzalez, M. P., Rico-Villademoros, R., Bascaran, M. T., Sarasa, P., & Clayton, A. (2000). Validation of the Spanish version of the Changes in Sexual Functioning Questionnaire-CSFQ. Journal of Sex & Marital Therapy, 26(2), 119–131. https://doi.org/10.1080/009262300278523
Clayton, A. H., McGarvey, E. L., & Clavet, G. J. (1997). The Changes in Sexual Functioning Questionnaire (CSFQ): Development, reliability, and validity. Psychopharmacology Bulletin, 33(4), 731–745. PMID: 9493480
Clayton, A. H., McGarvey, E. L., Clavet, G. J., & Piazza, L. (1997). Comparison of sexual functioning in clinical and non-clinical populations using the Changes in Sexual Functioning Questionnaire (CSFQ). Psychopharmacology Bulletin, 33(4), 747–753. PMID: 9493481
Clayton, A. H., Pradko, J. F., Croft, H. A., Montano, C. B., Leadbetter, R. A., Bolden-Watson, C., … & Metz, A. (2002). Prevalence of sexual dysfunction among newer antidepressants. The Journal of Clinical Psychiatry, 63(4), 357–366. https://doi.org/10.4088/jcp.v63n0414
Derogatis, L. R. (1997). The Derogatis Interview for Sexual Functioning (DISF/DISF-SR): An introductory report. Journal of Sex & Marital Therapy, 23(4), 291–304. https://doi.org/10.1080/00926239708403933
Kaplan, H. S. (1974). The New Sex Therapy: Active Treatment of Sexual Dysfunctions. Brunner/Mazel.
Kaplan, H. S. (1979). Disorders of Sexual Desire and Other New Concepts and Techniques in Sex Therapy. Brunner/Mazel.
Keller, A., McGarvey, E. L., & Clayton, A. H. (2006). Reliability and construct validity of the Changes in Sexual Functioning Questionnaire Short-Form (CSFQ-14). Journal of Sex & Marital Therapy, 32(1), 43–52. https://doi.org/10.1080/00926230500232909
Lagana, L., McGarvey, E. L., Classen, C., & Koopman, C. (2001). Psychosexual dysfunction among gynecological cancer survivors. Journal of Clinical Psychology in Medical Settings, 8(1), 73–84. https://doi.org/10.1023/A:1009589808381
Masters, W. H., & Johnson, V. E. (1966). Human Sexual Response. Little, Brown and Company.
Warnock, J. K., Swanson, S. G., Boren, R. W., Zipfel, L. M., & Brennan, J. J. (2005). Combined esterified estrogen and methyltestosterone versus esterified estrogens alone in the treatment of loss of sexual interest in surgically-menopausal women. Menopause, 12(4), 374–384. https://doi.org/10.1097/01.GME.0000155204.60647.E5